Risk factors

Marker Therapeutics (MRKR) risk factors

Item 1A of every Marker Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open MRKR in Gloom →
Marker Therapeutics' chart, financials and news, free in your browser.Open MRKR in Gloom →
  • FY2025 10-K risk factors
    49 risks3 new13 dropped8 reworded

    Marker now emphasizes outsourced manufacturing: no cGMP facility, BCM reliance, and Cellipont's MT-601 work ahead of a 2026 lymphoma trial.

    Filed Mar 18, 2026
  • FY2024 10-K risk factors
    59 risks

    Clinical stage immunotherapy company with a history of continuous operating losses.

    Filed Mar 31, 2025